MOLN
Molecular Partners is a Swiss biotechnology company focused on developing DARPin-based therapeutics for cancer and other serious diseases. The company specializes in radiopharmaceuticals, immune cell engagers, and multi-specific DARPins, including Radio-DARPins and Switch-DARPins, to go beyond today’s cancer treatments. Its pipeline highlights multispecific and targeted approaches for solid tumors and hematologic cancers, with programs such as DLL3 and other cancer targets. Headquartered in Switzerland, Molecular Partners collaborates with partners and maintains an international presence in oncology research.
No recent news for this company.